
USA - NASDAQ:ENTL -
The current stock price of ENTL is 24 null. In the past month the price decreased by -0.25%. In the past year, price increased by 78.44%.
Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota.
Entellus Medical Inc.
3600 HOLLY LANE NORTH SUITE 40
PLYMOUTH MN 55447
CEO: Robert S. White
Phone: 763-463-1595
Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota.
The current stock price of ENTL is 24 null. The price decreased by -0.04% in the last trading session.
ENTL does not pay a dividend.
ENTL has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Entellus Medical Inc. (ENTL) has a market capitalization of 617.52M null. This makes ENTL a Small Cap stock.
You can find the ownership structure of Entellus Medical Inc. (ENTL) on the Ownership tab.
ChartMill assigns a technical rating of 8 / 10 to ENTL. When comparing the yearly performance of all stocks, ENTL is one of the better performing stocks in the market, outperforming 95.45% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to ENTL. Both the profitability and financial health of ENTL have multiple concerns.
Over the last trailing twelve months ENTL reported a non-GAAP Earnings per Share(EPS) of -1.2829. The EPS increased by 6.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -31.21% | ||
| ROA | -11.13% | ||
| ROE | -21.66% | ||
| Debt/Equity | 0.32 |